Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 106

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 106
---
 statute of limitations. If we are or become a PFIC, you should consult your tax advisor regarding any reporting requirements that may
apply to you.

You should consult your tax advisor regarding the application of the PFIC rules to your investment in
Ordinary Shares.

Information Reporting and Backup Withholding

Any dividend payments with respect to Ordinary Shares and proceeds from the sale, exchange, redemption or other disposition of
Ordinary Shares may be subject to information reporting to the U.S. Internal Revenue Service and possible United States backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification
number and makes any other required certification or who otherwise establishes an exemption from backup withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification on U.S. Internal Revenue
Service Form W-9. U.S. Holders should consult their tax advisors regarding the application of the United States information reporting and backup withholding rules.

Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal
income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the U.S. Internal Revenue Service and furnishing any required information.

Additional Reporting Requirements

Certain U.S. Holders who are individuals (and certain entities) are required to report information relating to an interest in
our Ordinary Shares, subject to certain exceptions (including an exception for Ordinary Shares held in accounts maintained by certain financial institutions). U.S. Holders should consult their tax advisors regarding the effect, if any, of these
rules on the acquisition, ownership and disposition of our Ordinary Shares, and the significant penalties for non-compliance.

34

PLAN OF DISTRIBUTION

We have entered into a Sales Agreement with the Sales Agent under which we may issue and sell up to $150,000,000 of the
Ordinary Shares from time to time through Cantor as our Sales Agent. Sales of the Ordinary Shares, if any, will be made by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act,
including sales made directly on or through Nasdaq, on or through any other existing trading market for the Ordinary Shares or to or through a market maker. As of September 10, 2025, we have not sold any Ordinary Shares under the Sales Agreement.

The Sales Agent will offer the Ordinary Shares subject